A practical example of CCS implementation from our own operations
How is Contamination Control Strategy (CCS) applied in real operations? This article shares insights from Aptar Pharma Injectables, based on an internal review of practices across sites and functions, highlighting system consistency, governance and day-to-day execution.
CCS is well established as a system from a regulatory perspective. Its impact depends on how consistently it is translated into operational practice.
The focus quickly turned to how CCS principles are applied consistently across day-to-day operations, and how they can support transformation in practice.
Over the past two years, CCS has become a central topic in our industry.
Frameworks, expectations and guidance are now well-established and widely documented. Yet far less has been written about how CCS is applied in day-to-day operations.
As a supplier of elastomeric closure solutions for injectable drug products, Aptar Pharma is directly involved in contamination control. As Annex 1 expectations are implemented, this increasingly extends across the supply chain.
At Aptar Pharma, this marked the starting point of our approach to CCS in practice, beginning with an internal mock inspection across our sites.
As a first step, we assessed the consistency with which contamination control is structured and applied across our operations and how CCS principles could be leveraged as a source of transformation.
This blog shares the first part of that reflection: how we approached CCS across our operations, and what we observed along the way.
From strong foundations to system consistency
In 2024, Aptar Pharma Injectables conducted an internal mock inspection across its sites, designed to reflect EU GMP Annex 1 expectations.
The intent was to look at operations as a whole and assess how clearly the contamination control approach could be demonstrated across different environments and activities.
The outcome confirmed that the fundamentals were solid:
- Manufacturing processes were robust
- Control measures were in place
- Teams brought strong experience and a well-established quality culture.
The review also highlighted the importance of ensuring that these elements are consistently structured and connected as part of a broader CCS approach.
It further brought into view a number of operational realities that are familiar across the industry. Aging equipment fleets, legacy material flows and packaging practices such as the continued presence of wood pallets are not unusual in global manufacturing environments. These are the kinds of conditions many sites continue to manage, whether at suppliers, customer facilities or elsewhere across the industry.
Bringing these realities into the conversation matters. It helps move CCS away from abstract principles and closer to the environments where contamination control is actually maintained every day.
Attention naturally moved toward how existing controls are organized into a system that is clear, coherent and consistently applied.
Translating CCS into an operational approach
This led to a closer look at how CCS is reflected in daily operations.
Greater attention was placed on how contamination control is structured, applied and sustained over time.
This was supported by:
- Dedicated program leadership
- Coordinated workstreams addressing key dimensions of contamination control
- Governance at executive level
- Clearly defined objectives and milestones.
Over time, CCS became increasingly visible in everyday practices and decisions across the organization.
That progression also helped frame a practical question: how can operational realities that are common across the industry be managed more consistently, documented more clearly and addressed in a way that strengthens confidence over time.
What CCS implementation means in practice
Implementing CCS in practice brings a number of implications.
Regulatory expectations place CCS as a living, risk-based system that requires continuous attention. This calls for alignment between how risks are identified, how controls are applied and how performance is monitored over time.
In our experience, this takes shape through:
- The connection between risk assessment and operational decisions
- Alignment of practices across functions and sites
- Integration with quality systems such as change control, deviations and CAPA
- Continuous review and improvement based on observed performance.
It also broadens the perspective on where contamination control is managed.
It extends across flows, interfaces and day-to-day practices throughout the operational environment, beyond specific technical systems or controlled areas.
This is also why practical examples matter. When discussions remain too general, CCS can sound distant from the realities of industrial operations. Speaking openly about common operational constraints gives the subject more relevance and makes the conversation more useful to those facing similar conditions across pharma manufacturing.
Key observations from this first step
As Aptar Pharma progressed, several observations emerged.
- CCS reflects how well a system is structured
The objective is to demonstrate how different controls work together in a consistent and auditable way.
- Contamination control spans across operational interfaces
Relevant risks can arise across environments, flows and interactions, not only within defined technical areas.
- Operational realities deserve to be addressed directly
Ageing assets, legacy flows and longstanding material practices are part of the industrial context many organizations continue to manage. Addressing them openly helps make CCS more tangible and more credible.
- Consistency in execution is essential
The effectiveness of CCS depends on how reliably it is applied in daily operations.
Looking ahead
CCS is now firmly anchored in the regulatory landscape, with expectations intensifying since it came into force.
The focus has shifted to execution, ensuring consistent application, continuous verification, and measurable, tangible outcomes.
CCS becomes meaningful through the way it is applied, structured and maintained in real operational conditions.
We understand our contribution: our customers’ CCS must seamlessly take over where ours ends for them to be successful.
This perspective guided the approach taken within Aptar Pharma Injectables.
In the next blog, we will share how this translated concretely into the way operations were reviewed with a fresh perspective.
Read more about our advanced parenteral closure solutions.
